« Return to News | CROs/Service Providers

Kendle 3Q Revenues, Net Income Slide

Thursday, November 5, 2009 09:16 AM

Kendle, a global contract research organization, reported third quarter net income slipped to $8.8 million or $0.59 per diluted share for the third quarter of 2009, compared with net income of $9.4 million or $0.62 per diluted share for the third quarter of 2008.  

The company said execution of cost control initiatives helped it maintain net income. Net revenues for the third quarter were $104.6 million, down slightly from the second quarter and off $20 million from the year ago quarter.

On a pro forma basis, excluding the additional non-cash interest and restructuring charges, net income per diluted share for the third quarter of 2009 was $0.71 compared with $0.73 per diluted share for the third quarter of 2008.

Operating income for the quarter increased from the second quarter of 2009 to $15.5 million or 14.9%.

New business awards for the third quarter totaled $137.2 million, up from $132 million in the second quarter of 2009. Gross book to bill for the third quarter was 1.3 to 1.0.

Contract cancellations for the quarter were $53.8 million or 6.1% of the company's backlog at June 30, representing a net book-to-bill of 0.8 to 1.0. Total business authorizations amounted to $84 million at Sept. 30, 2009.

Cash, cash equivalents and marketable securities at Sept. 30, 2009 totaled $57.7 million.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.